<DOC>
	<DOCNO>NCT02420496</DOCNO>
	<brief_summary>To investigate effect enteral fish oil UDCA time cholestasis resolution marker parenteral nutrition-associated liver disease .</brief_summary>
	<brief_title>Enteral Fish Oil Superior Ursodeoxycholic Acid ( UDCA ) Placebo Treatment Cholestasis Infants</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Neonates admit Neonatal Intensive Care Unit ( NICU ) University Hospital ( UH ) San Antonio , Texas , : 1 . Are &gt; 14 day old &lt; 24 month age 2 . Have serum direct bilirubin â‰¥2 mg/dL 3 . Are receive &lt; 3 g/k/day Intralipid via TPN 4 . Are expect remain hospitalized least additional 21 day 1 . Have congenitally lethal condition ( e.g . Trisomy 13 ) 2 . Have clinically severe bleed able manage routine measure 3 . Have evidence viral hepatitis primary liver disease etiology cholestasis 4 . Have health problem survival extremely unlikely even cholestasis improve 5 . Known allergy egg fish product 6 . Receiving IV Fish oil 7 . Phenobarbital therapy enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Parental nutrition</keyword>
	<keyword>associate</keyword>
</DOC>